Literature DB >> 1901758

The roles of gamma-interferon and tumor necrosis factor alpha in an experimental rat model of cancer cachexia.

H N Langstein1, G M Doherty, D L Fraker, C M Buresh, J A Norton.   

Abstract

Administration of repetitive sublethal doses of either recombinant human tumor necrosis factor (TNF) or recombinant murine gamma-interferon (IFN) to non-tumor-bearing (NTB) rats caused a significant decline in food intake and body weight. After 3 days rats became resistant to the anorectic and weight loss effects of TNF but maintained persistent diminished food intake and diminished body weight gain while receiving recombinant murine IFN. Passive immunization against recombinant rat gamma-interferon allowed cachectic tumor-bearing (TB) rats to eat more food, have a lesser decline in body weight, live longer, and tolerate larger tumors than similar TB rats given nonspecific control antibody. TB rats treated with an antisera to recombinant murine TNF, which was 100% protective when given to NTB rats 6 h before a lethal endotoxin challenge, did not differ significantly from TB rats treated with control antibody with respect to food intake, body weight, survival, or tumor size. Serum levels of TNF or IFN were not detectable in cachectic tumor-bearing rats. The data indicate that the administration of exogenous IFN can simulate cachexia in NTB rats and that passive immunization against it can partially reverse the cachectic changes associated with cancer and prolong survival. These findings suggest that gamma-interferon may be an important mediator of cachexia in this rat tumor model.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901758

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  An intermediate dose of LCMV clone 13 causes prolonged morbidity that is maintained by CD4+ T cells.

Authors:  Andrew Stamm; Laura Valentine; Rashaun Potts; Mary Premenko-Lanier
Journal:  Virology       Date:  2012-02-04       Impact factor: 3.616

2.  Fenofibrate prevents skeletal muscle loss in mice with lung cancer.

Authors:  Marcus D Goncalves; Seo-Kyoung Hwang; Chantal Pauli; Charles J Murphy; Zhe Cheng; Benjamin D Hopkins; David Wu; Ryan M Loughran; Brooke M Emerling; Guoan Zhang; Douglas T Fearon; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

3.  Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer.

Authors:  M D Goncalves; S Taylor; D F Halpenny; E Schwitzer; S Gandelman; J Jackson; A Lukose; A J Plodkowski; K S Tan; M Dunphy; L W Jones; R J Downey
Journal:  Clin Radiol       Date:  2018-01-06       Impact factor: 2.350

4.  Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia.

Authors:  K G Billingsley; D L Fraker; G Strassmann; C Loeser; H M Fliot; H R Alexander
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

Review 5.  Cancer cachexia, mechanism and treatment.

Authors:  Tomoyoshi Aoyagi; Krista P Terracina; Ali Raza; Hisahiro Matsubara; Kazuaki Takabe
Journal:  World J Gastrointest Oncol       Date:  2015-04-15

6.  Evidence for the involvement of interleukin 6 in experimental cancer cachexia.

Authors:  G Strassmann; M Fong; J S Kenney; C O Jacob
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

7.  Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.

Authors:  J N Gordon; T M Trebble; R D Ellis; H D Duncan; T Johns; P M Goggin
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 8.  Are cytokines possible mediators of cancer cachexia?

Authors:  Y Noguchi; T Yoshikawa; A Matsumoto; G Svaninger; J Gelin
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

9.  Decrease of glutaminase expression by interferon-gamma in human intestinal epithelial cells.

Authors:  P Sarantos; Z Abouhamze; E M Copeland; W W Souba
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

10.  Increased serum concentrations of soluble tumor necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer.

Authors:  M Shibata; M Takekawa; S Amano
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.